Tumor thymidylate synthase 1494del6 genotype as a prognostic factor in colorectal cancer patients receiving fluorouracil-based adjuvant treatment.
暂无分享,去创建一个
E. Guinó | V. Moreno | G. Capellá | A. Villanueva | A. Figueras | M. Peinado | D. Molleví | T. Serrano | J. de Oca | M. Navarro | F. Vilardell | L. Pareja | M. Martínez-Iniesta | J. Germà | E. Dotor | M. Cuatrecases
[1] A. Jakobsen,et al. Thymidylate synthase and methylenetetrahydrofolate reductase gene polymorphism in normal tissue as predictors of fluorouracil sensitivity. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[2] T. Merriman,et al. Association of thymidylate synthase polymorphisms with gastric cancer susceptibility , 2004, International journal of cancer.
[3] M. Baiget,et al. Single nucleotide polymorphism in the 5′ tandem repeat sequences of thymidylate synthase gene predicts for response to fluorouracil‐based chemotherapy in advanced colorectal cancer patients , 2004, International journal of cancer.
[4] D. Tregouet,et al. Thymidylate Synthase Gene Polymorphism Predicts Toxicity in Colorectal Cancer Patients Receiving 5-Fluorouracil-based Chemotherapy , 2004, Clinical Cancer Research.
[5] J. Berlin,et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. , 2004, The New England journal of medicine.
[6] T. Hickish,et al. Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. , 2004, The New England journal of medicine.
[7] S. Groshen,et al. A 6 bp polymorphism in the thymidylate synthase gene causes message instability and is associated with decreased intratumoral TS mRNA levels. , 2004, Pharmacogenetics.
[8] F. Kaye,et al. Thymidylate synthase as an oncogene: a novel role for an essential DNA synthesis enzyme. , 2004, Cancer cell.
[9] G. Parmigiani,et al. Digital karyotyping identifies thymidylate synthase amplification as a mechanism of resistance to 5-fluorouracil in metastatic colorectal cancer patients. , 2004, Proceedings of the National Academy of Sciences of the United States of America.
[10] E. Hitre,et al. Heterozygote deficiency in thymidylate synthase enhancer region polymorphism genotype distribution in Hungarian colorectal cancer patients , 2004, International journal of cancer.
[11] A. Matakidou,et al. Thymidylate synthase expression and prognosis in colorectal cancer: a systematic review and meta-analysis. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[12] K. Hayashi,et al. Loss of Heterozygosity at the Thymidylate Synthase (TS) Locus on Chromosome 18 Affects Tumor Response and Survival in Individuals Heterozygous for a 28-bp Polymorphism in the TS Gene , 2004, Clinical Cancer Research.
[13] Rebecca A Mosig,et al. Polymorphism in the thymidylate synthase promoter enhancer region modifies the risk and survival of colorectal cancer. , 2003, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.
[14] G. Watanabe,et al. Identification and functional analysis of single nucleotide polymorphism in the tandem repeat sequence of thymidylate synthase gene. , 2003, Cancer research.
[15] S. Hidaka,et al. Polymorphism in the thymidylate synthase promoter enhancer region is not an efficacious marker for tumor sensitivity to 5-fluorouracil-based oral adjuvant chemotherapy in colorectal cancer. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.
[16] H. Lenz,et al. A novel single nucleotide polymorphism within the 5' tandem repeat polymorphism of the thymidylate synthase gene abolishes USF-1 binding and alters transcriptional activity. , 2003, Cancer research.
[17] P. Johnston,et al. 5-Fluorouracil: mechanisms of action and clinical strategies , 2003, Nature Reviews Cancer.
[18] G. Watanabe,et al. Functional Polymorphism of the Thymidylate Synthase Gene in Colorectal Cancer Accompanied by Frequent Loss of Heterozygosity , 2002, Japanese journal of cancer research : Gann.
[19] N. Magné,et al. Prognostic value of tumoral thymidylate synthase and p53 in metastatic colorectal cancer patients receiving fluorouracil-based chemotherapy: phenotypic and genotypic analyses. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[20] C. Ulrich,et al. Thymidylate synthase promoter polymorphism, interaction with folate intake, and risk of colorectal adenomas. , 2002, Cancer research.
[21] D. Sargent,et al. Investigation of the prognostic and predictive value of thymidylate synthase, p53, and Ki-67 in patients with locally advanced colon cancer. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[22] H. Blomgren,et al. Thymidylate synthase expression in colorectal cancer: a prognostic and predictive marker of benefit from adjuvant fluorouracil-based chemotherapy. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[23] D. Schaid,et al. Score tests for association between traits and haplotypes when linkage phase is ambiguous. , 2002, American journal of human genetics.
[24] G. Watanabe,et al. Different lengths of a polymorphic repeat sequence in the thymidylate synthase gene affect translational efficiency but not its gene expression. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.
[25] B. Iacopetta,et al. A polymorphism in the enhancer region of the thymidylate synthase promoter influences the survival of colorectal cancer patients treated with 5-fluorouracil , 2001, British Journal of Cancer.
[26] H. McLeod,et al. Polymorphism in the thymidylate synthase promoter enhancer region in colorectal cancer. , 2001, International journal of oncology.
[27] P. Laurent-Puig,et al. Thymidylate synthase promoter polymorphism. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[28] J. García-Foncillas,et al. Polymorphisms of the repeated sequences in the enhancer region of the thymidylate synthase gene promoter may predict downstaging after preoperative chemoradiation in rectal cancer. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[29] S. Groshen,et al. Thymidylate synthase gene polymorphism determines response and toxicity of 5-FU chemotherapy , 2001, The Pharmacogenomics Journal.
[30] C. Ulrich,et al. Searching expressed sequence tag databases: discovery and confirmation of a common polymorphism in the thymidylate synthase gene. , 2000, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.
[31] L. Saltz,et al. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. , 2000, The New England journal of medicine.
[32] C. Wilson,et al. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[33] F. Lévi,et al. Phase III multicenter randomized trial of oxaliplatin added to chronomodulated fluorouracil-leucovorin as first-line treatment of metastatic colorectal cancer. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[34] F. Berger,et al. Mechanisms of acquired resistance to thymidylate synthase inhibitors: the role of enzyme stability. , 1999, Molecular pharmacology.
[35] K. Kawakami,et al. Polymorphic tandem repeats in the thymidylate synthase gene is associated with its protein expression in human gastrointestinal cancers. , 1999, Anticancer research.
[36] F. Maley,et al. Probing the Folate-binding Site of Human Thymidylate Synthase by Site-directed Mutagenesis , 1998, The Journal of Biological Chemistry.
[37] G. Capellá,et al. Disruption of the antiproliferative TGF-β signaling pathways in human pancreatic cancer cells , 1998, Oncogene.
[38] L. Loeb,et al. Random Sequence Mutagenesis and Resistance to 5-Fluorouridine in Human Thymidylate Synthases* , 1998, The Journal of Biological Chemistry.
[39] S. Groshen,et al. p53 point mutations and thymidylate synthase messenger RNA levels in disseminated colorectal cancer: an analysis of response and survival. , 1998, Clinical cancer research : an official journal of the American Association for Cancer Research.
[40] N. Horie,et al. Functional analysis and DNA polymorphism of the tandemly repeated sequences in the 5'-terminal regulatory region of the human gene for thymidylate synthase. , 1995, Cell structure and function.
[41] P. Johnston,et al. Thymidylate synthase gene and protein expression correlate and are associated with response to 5-fluorouracil in human colorectal and gastric tumors. , 1995, Cancer research.
[42] Y. Nakamura,et al. Allelotype of colorectal carcinomas. , 1989, Science.
[43] S. Altman,et al. Role in translation of a triple tandemly repeated sequence in the 5'-untranslated region of human thymidylate synthase mRNA. , 1987, Nucleic acids research.
[44] P. Danenberg. Thymidylate synthetase - a target enzyme in cancer chemotherapy. , 1977, Biochimica et biophysica acta.